Discovery of W478, a novel SHMT2 inhibitor for the treatment of esophageal carcinoma
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.109028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Hafiz Muhammad Bilal Akram und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Metabolism Dysregulation & Prevention and Treatment of Esophageal Cancer, Key Laboratory of Advanced Pharmaceutical Technolog…. Hauptthemen laut MEDLINE: Glycine Hydroxymethyltransferase, Esophageal Neoplasms, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Zhengzhou University, Startup Research Fund of Zhengzhou University.
Abstract (Originalsprache)
Esophageal cancer has been regarded as a serious malignancy due to its poor prognosis and high mortality rate. Serine hydroxymethyltransferase 2 (SHMT2) is emerging as an attractive target for esophageal cancer therapy. Compound W478 was identified as a potent SHMT2 inhibitor with an IC50 value of 1.21 μM, especially whose chemical structure is distinct from the reported SHMT2 inhibitors. Both cellular thermal shift assay and isothermal titration calorimetry experiments showed that compound W478 tightly bound to SHMT2 (KD = 10.6 ± 1.2 μM). The molecular docking analysis revealed its binding at the folate binding site of SHMT2. Moreover, compound W478 exhibited a significant antiproliferative effect on human esophageal cancer cell lines, KYSE-450 and KYSE-70 cells (IC50 = 1.62 μM, 1.18 μM, respectively). The wound healing and transwell assays showed that compound W478 could inhibit the migratory and invasive potential of KYSE-450 and KYSE-70 cells in a dose-dependent manner. Further studies demonstrated that compound W478 could induce cell arrest at the G2/M phase and promote cell apoptosis and ROS production in KYSE-450 and KYSE-70 cells. These findings indicated that compound W478 could serve as a promising lead compound for the development of SHMT2 inhibitor to address esophageal carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Metabolism Dysregulation & Prevention and Treatment of Esophageal Cancer, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, School of Pharmaceutical Sciences,…
- Henan Key Laboratory for Esophageal Cancer Research and National Key Laboratory of Metabolism Disorder and Esophageal Cancer Prevention & Treatment of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 45005…
- State Key Laboratory of Metabolism Dysregulation & Prevention and Treatment of Esophageal Cancer, Academy of Medical Sciences, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou 450052,…
Förderung
- Zhengzhou University
- Startup Research Fund of Zhengzhou University
Zitieren
APA
Akram, H. M. B., Liu, Y., Dong, J., Zhao, X., Wang, L., Zhao, W., Liu, H., Ma, L., & Han, C. (2025). Discovery of W478, a novel SHMT2 inhibitor for the treatment of esophageal carcinoma. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109028
Vancouver
Akram HMB, Liu Y, Dong J, Zhao X, Wang L, Zhao W, et al. Discovery of W478, a novel SHMT2 inhibitor for the treatment of esophageal carcinoma. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.109028
BibTeX
@article{Akram2025,
author = {Akram, Hafiz Muhammad Bilal and Liu, Yulin and Dong, Jianshu and Zhao, Xueke and Wang, Lidong and Zhao, Wen and Liu, Hongmin and Ma, Liying and Han, Cong},
title = {Discovery of W478, a novel SHMT2 inhibitor for the treatment of esophageal carcinoma},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.109028}
}
EUVIMED